The short answer
Melatonin and valproate have been studied together under supervision. Some trials found better sleep without increased daytime sleepiness, so universal avoidance is not supported. Individual drowsiness remains possible, and people with epilepsy should use melatonin with medical supervision.
What this answer covers
Oral melatonin with oral valproate, sodium valproate or valproic acid in specified trials; release form, age, indication and dose limit generalization.
- Supplement or preparation
- Melatonin
- Medication ingredient
- valproate
Direct studies found a mixed picture
An adult trial of 104 randomized participants added melatonin or placebo to valproate for eight weeks. Sleep quality and some seizure outcomes improved, while daytime sleepiness scores did not differ significantly. A smaller pediatric sodium-valproate trial also found no significant difference in change in daytime drowsiness. These results do not exclude an individual reaction.
Better sleep is not proven seizure control
A separate study of 60 adults receiving valproic acid found improved sleep and seizure severity with melatonin, but no significant reduction in seizure frequency or EEG abnormalities. It reported no adverse reaction. The findings are limited to selected patients and do not justify replacing prescribed treatment or promising seizure prevention.
Why supervision still matters
Valproate can cause drowsiness and slowed thinking. Melatonin can also cause daytime drowsiness, and NCCIH specifically recommends medical supervision for people with epilepsy. Age, other sedatives and the actual melatonin formulation should be part of that review.
No blanket spacing or avoidance rule
The trials do not establish that everyone must avoid melatonin or separate it from valproate by a set number of hours. Taking melatonin before bedtime in a study was a sleep regimen, not a tested interaction-prevention interval. Discuss troublesome daytime sleepiness and do not drive while impaired or stop valproate abruptly.
Evidence and practical considerations
Timing & monitoring
Direct supervised trials do not support universal avoidance or a protective separation interval; epilepsy-specific supervision remains advised.
- Exact scope
- Oral melatonin with oral valproate, sodium valproate or valproic acid in specified trials; release form, age, indication and dose limit generalization. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Evidence does not quantify all-product interaction risk; source-specific limits apply.
Factors that may matter: Indication; Exact preparation; Other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Daytime drowsiness can occur; people with epilepsy need medical supervision when using melatonin.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Source 3: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 104 adults randomized with generalized epilepsy and generalized onset motor seizures; 88 completed.
Sleep quality and some seizure outcomes improved; change in Epworth Sleepiness Scale did not differ significantly (P=0.621).
How this applies: Applies only to the stated preparation, population and measured endpoints.
Abstract-only safety detail; selected population, short duration and incomplete follow-up. Does not prove absence of individual sedation.
Source 4: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 31 children aged 3-12 years with epilepsy on sodium valproate monotherapy.
Improved total sleep and parasomnia scores; no significant between-group difference in percentage change in daytime drowsiness scores.
How this applies: Applies only to the stated preparation, population and measured endpoints.
Small pediatric study; dose and duration are not specified in the inspected abstract, so not supplied as facts.
Source 5: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults with generalized tonic-clonic seizures alone under valproic acid treatment.
Sleep quality and seizure severity improved; seizure frequency and EEG did not differ significantly. Authors reported no adverse reaction to melatonin.
How this applies: Applies only to the stated preparation, population and measured endpoints.
Small selected population; analysis/reporting limitations and limited safety detail. No protective interval between valproate and melatonin was tested.
Research assessment: · Open full citations ↗
Side effects & toxicity
Individual additive drowsiness is possible, but direct adult and pediatric trials found no significant between-group daytime sleepiness difference. Severe CNS depression or a consistent added sedation effect is not established.
- Exact scope
- Oral melatonin with oral valproate, sodium valproate or valproic acid in specified trials; release form, age, indication and dose limit generalization. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Evidence does not quantify all-product interaction risk; source-specific limits apply.
Factors that may matter: Indication; Exact preparation; Other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Daytime drowsiness can occur; people with epilepsy need medical supervision when using melatonin.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Source 3: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 104 adults randomized with generalized epilepsy and generalized onset motor seizures; 88 completed.
Sleep quality and some seizure outcomes improved; change in Epworth Sleepiness Scale did not differ significantly (P=0.621).
How this applies: Applies only to the stated preparation, population and measured endpoints.
Abstract-only safety detail; selected population, short duration and incomplete follow-up. Does not prove absence of individual sedation.
Source 4: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 31 children aged 3-12 years with epilepsy on sodium valproate monotherapy.
Improved total sleep and parasomnia scores; no significant between-group difference in percentage change in daytime drowsiness scores.
How this applies: Applies only to the stated preparation, population and measured endpoints.
Small pediatric study; dose and duration are not specified in the inspected abstract, so not supplied as facts.
Source 5: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults with generalized tonic-clonic seizures alone under valproic acid treatment.
Sleep quality and seizure severity improved; seizure frequency and EEG did not differ significantly. Authors reported no adverse reaction to melatonin.
How this applies: Applies only to the stated preparation, population and measured endpoints.
Small selected population; analysis/reporting limitations and limited safety detail. No protective interval between valproate and melatonin was tested.
Research assessment: · Open full citations ↗
Side effects & toxicity
Individual added drowsiness is possible; use the preparation-specific evidence and medical supervision rather than treating the combination as proven toxic or safe.
- Exact scope
- Oral melatonin with oral valproate, sodium valproate or valproic acid in specified trials; release form, age, indication and dose limit generalization. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Direct melatonin trials have null daytime-sleepiness signals; rare or individual impairment is not excluded.
Factors that may matter: Exact preparation; Age; Other sedatives.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Daytime drowsiness can occur; people with epilepsy need medical supervision when using melatonin.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Source 3: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 104 adults randomized with generalized epilepsy and generalized onset motor seizures; 88 completed.
Sleep quality and some seizure outcomes improved; change in Epworth Sleepiness Scale did not differ significantly (P=0.621).
How this applies: Applies only to the stated preparation, population and measured endpoints.
Abstract-only safety detail; selected population, short duration and incomplete follow-up. Does not prove absence of individual sedation.
Source 4: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 31 children aged 3-12 years with epilepsy on sodium valproate monotherapy.
Improved total sleep and parasomnia scores; no significant between-group difference in percentage change in daytime drowsiness scores.
How this applies: Applies only to the stated preparation, population and measured endpoints.
Small pediatric study; dose and duration are not specified in the inspected abstract, so not supplied as facts.
Source 5: original human randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 60 adults with generalized tonic-clonic seizures alone under valproic acid treatment.
Sleep quality and seizure severity improved; seizure frequency and EEG did not differ significantly. Authors reported no adverse reaction to melatonin.
How this applies: Applies only to the stated preparation, population and measured endpoints.
Small selected population; analysis/reporting limitations and limited safety detail. No protective interval between valproate and melatonin was tested.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared article with direct-study limits, preparation boundaries and claim-specific conclusions. | |
| Research summary published |
Article revision: ed17b288a0e6cc9a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.